Urology News and Research

Latest Urology News and Research

TURis plasma vaporization electrode for benign prostatic hyperplasia therapy

The TURis plasma vaporization electrode does not cut off tissue with a loop, but energetically vaporizes the tissue with a small button electrode. With the help of the latest plasma technology, cells can be removed by merely gliding the electrode over the prostate tissue.

From Evident Corporation - Life Sciences 9 Sep 2009

Advocacy campaign to fight reimbursement cuts for POC urine drug screen devices

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, has announced the launch of an advocacy campaign to fight reimbursement cuts to point-of-care (POC) urine drug screen devices.

9 Sep 2009

Microline PENTAX launches rebranded website and new company logo

Microline PENTAX, Inc., a leading manufacturer of reposable instruments for minimally invasive surgery, announced today that it has completed the change of its corporate name to Microline Surgical, Inc. The company will also issue a new logo and launch a rebranded website.

8 Sep 2009

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH), a common and bothersome urological condition that affects more than 50 million men worldwide.

8 Sep 2009

Regurin XL capsule for the treatment of OAB launched in UK

Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R) XL provides rapid, significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects(2-7).

7 Sep 2009

Two new da Vinci Si HD Surgical System robots added to Swedish Medical Center

As one of the first medical centers in the Northwest to perform robot-assisted surgery, Swedish Medical Center is home to the fastest-growing and most experienced robot-assisted surgical program in the region. Swedish established the multidisciplinary robot-assisted surgical program in 2005 and has since performed more than 2,000 robot-assisted surgeries, more than any other program in the region.

4 Sep 2009

Periurethral suspension technique results in greater continence rates after RALIP

The September issue of European Urology, the official journal of the European Association of Urology, features an article and a video in the Surgery in Motion section by Vipul R. Patel et al, showing that the periurethral suspension technique results in significantly greater continence rates at 3 months after robot-assisted laparoscopic radical prostatectomy (RALP).

4 Sep 2009

Giant Eagle offers generic prescription antibiotics for free at its in-store pharmacies

At a time when many families affected by a difficult economy are struggling with the costs of prescription medications, supermarket retailer Giant Eagle, Inc. is making ten broadly used generic prescription antibiotics in 46 common dosages available for free every day at all of its 210 in-store pharmacies.

4 Sep 2009

Top cancer hospitals have Elekta solutions for information management

Y chromosome may be responsible for a range of sex disorders

The unique mechanism behind the evolutionary survival of the human Y chromosome may also be responsible for a range of sex disorders, from failed sperm production to sex reversal to Turner Syndrome.

3 Sep 2009

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.

3 Sep 2009

Uroplasty highlights the result of OrBIT trial of its Urgent PC System

Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results published in the September, 2009 edition of THE JOURNAL OF UROLOGY(R) from the OrBIT trial of its Urgent PC System.

3 Sep 2009

New findings on molecular imaging and prostate cancer

A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.

2 Sep 2009

Retail clinics offer better quality care at lower costs than other venues

A new study by Rand Corporation, published in the Annals of Internal Medicine, concludes retail clinics provide quality care at lower costs and equal or better quality than other urgent care options.

1 Sep 2009

FDA approves Watson Pharmaceuticals' ANDA for Levonorgestrel tablets

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Levonorgestrel Tablets, 0.75 mg for over-the-counter use in women ages 17 and above, as well as for prescription use in women under the age of 17.

29 Aug 2009

TomoTherapy to discuss the uses of CT scanner-based device at the 10th Biennial ESTRO Conference

TomoTherapy Incorporated announced today that there will be more than 40 presentations at the 10th Biennial ESTRO Conference on Physics and Radiation Technology for Clinical Radiotherapy that explore use of the TomoTherapy treatment system. The TomoTherapy system -- a versatile, CT scanner-based device that integrates image guidance for increased treatment accuracy and helical radiation therapy delivery for enhanced tumor targeting -- is helping cancer centers advance patient care around the world.

28 Aug 2009

Resonant Medical's multi-anatomy Clarity System to be exhibited at ESTRO, Netherlands

Resonant Medical, an innovator in soft tissue planning, image-guidance and adaptive radiotherapy products, today announced that the Company will be exhibiting the next generation of its multi-anatomy Clarity System at the 10th Biennial Meeting of The European Society of Therapeutic Radiology and Oncologists (ESTRO), being held in Maastricht, Netherlands.

27 Aug 2009

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

Haber, Inc. (“Haber”), (OTC: HABE), a Delaware corporation headquartered in Arlington, Mass., with proprietary technologies in the separations sciences and environmentally friendly processing of gold bearing ores, announced today that it has formed a wholly owned subsidiary incorporated in Delaware called “EMP Diagnostics Inc.” (“EDI”). The business of the new company will focus on the application of Haber’s Electromolecular Propulsion technology (EMP). EMP is a separation technology that achieves unrivaled molecular separation speeds and has other unique capabilities not attainable with electrophoresis or liquid chromatography.

27 Aug 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.

24 Aug 2009

Urology News and Research

Latest Urology News and Research

TURis plasma vaporization electrode for benign prostatic hyperplasia therapy

Advocacy campaign to fight reimbursement cuts for POC urine drug screen devices

Microline PENTAX launches rebranded website and new company logo

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Regurin XL capsule for the treatment of OAB launched in UK

Two new da Vinci Si HD Surgical System robots added to Swedish Medical Center

Periurethral suspension technique results in greater continence rates after RALIP

Giant Eagle offers generic prescription antibiotics for free at its in-store pharmacies

Top cancer hospitals have Elekta solutions for information management

Y chromosome may be responsible for a range of sex disorders

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Uroplasty highlights the result of OrBIT trial of its Urgent PC System

New findings on molecular imaging and prostate cancer

Retail clinics offer better quality care at lower costs than other venues

FDA approves Watson Pharmaceuticals' ANDA for Levonorgestrel tablets

TomoTherapy to discuss the uses of CT scanner-based device at the 10th Biennial ESTRO Conference

Resonant Medical's multi-anatomy Clarity System to be exhibited at ESTRO, Netherlands

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Urology News and Research

Latest Urology News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in